JP2020529449A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529449A5
JP2020529449A5 JP2020506272A JP2020506272A JP2020529449A5 JP 2020529449 A5 JP2020529449 A5 JP 2020529449A5 JP 2020506272 A JP2020506272 A JP 2020506272A JP 2020506272 A JP2020506272 A JP 2020506272A JP 2020529449 A5 JP2020529449 A5 JP 2020529449A5
Authority
JP
Japan
Prior art keywords
compound
salt
alkyl
optionally substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020506272A
Other languages
English (en)
Japanese (ja)
Other versions
JP7281446B2 (ja
JP2020529449A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/045421 external-priority patent/WO2019060051A1/en
Publication of JP2020529449A publication Critical patent/JP2020529449A/ja
Publication of JP2020529449A5 publication Critical patent/JP2020529449A5/ja
Priority to JP2023028553A priority Critical patent/JP2023054360A/ja
Application granted granted Critical
Publication of JP7281446B2 publication Critical patent/JP7281446B2/ja
Priority to JP2024207992A priority patent/JP2025029026A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020506272A 2017-08-04 2018-08-06 高カリウム血症を処置するためのグリチルレチン酸誘導体 Active JP7281446B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023028553A JP2023054360A (ja) 2017-08-04 2023-02-27 高カリウム血症を処置するためのグリチルレチン酸誘導体
JP2024207992A JP2025029026A (ja) 2017-08-04 2024-11-29 高カリウム血症を処置するためのグリチルレチン酸誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541095P 2017-08-04 2017-08-04
US62/541,095 2017-08-04
PCT/US2018/045421 WO2019060051A1 (en) 2017-08-04 2018-08-06 GLYCYRRHETINIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERKALIEMIA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023028553A Division JP2023054360A (ja) 2017-08-04 2023-02-27 高カリウム血症を処置するためのグリチルレチン酸誘導体

Publications (3)

Publication Number Publication Date
JP2020529449A JP2020529449A (ja) 2020-10-08
JP2020529449A5 true JP2020529449A5 (https=) 2021-09-16
JP7281446B2 JP7281446B2 (ja) 2023-05-25

Family

ID=63364189

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020506272A Active JP7281446B2 (ja) 2017-08-04 2018-08-06 高カリウム血症を処置するためのグリチルレチン酸誘導体
JP2023028553A Withdrawn JP2023054360A (ja) 2017-08-04 2023-02-27 高カリウム血症を処置するためのグリチルレチン酸誘導体
JP2024207992A Pending JP2025029026A (ja) 2017-08-04 2024-11-29 高カリウム血症を処置するためのグリチルレチン酸誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023028553A Withdrawn JP2023054360A (ja) 2017-08-04 2023-02-27 高カリウム血症を処置するためのグリチルレチン酸誘導体
JP2024207992A Pending JP2025029026A (ja) 2017-08-04 2024-11-29 高カリウム血症を処置するためのグリチルレチン酸誘導体

Country Status (17)

Country Link
US (3) US11768319B2 (https=)
EP (2) EP3661945B1 (https=)
JP (3) JP7281446B2 (https=)
KR (2) KR20200074085A (https=)
CN (2) CN118440135A (https=)
AU (3) AU2018335130B2 (https=)
BR (1) BR112020002322A2 (https=)
CA (1) CA3071992A1 (https=)
EA (1) EA202090438A1 (https=)
IL (3) IL318937A (https=)
MA (1) MA49761A (https=)
MX (2) MX2020001412A (https=)
PH (1) PH12020500432A1 (https=)
SG (1) SG11202000950TA (https=)
UA (1) UA126584C2 (https=)
WO (1) WO2019060051A1 (https=)
ZA (2) ZA202001352B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260004570A (ko) * 2019-02-07 2026-01-08 알데릭스, 인코포레이티드 고칼륨혈증 치료에 사용하기 위한 글리시레틴산 유도체
CN111018938B (zh) * 2019-12-10 2021-05-25 中国人民解放军第二军医大学 一种五环三萜类甘草次酸衍生物及制备方法与应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
US5519008A (en) * 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
DK0612723T3 (da) 1993-02-20 1998-03-30 Hoechst Ag Substituerede benzoylguanidiner, fremgangsmåde til fremstilling, deres anvendelse som lægemiddel, som inhibitor af den cellulære Na+/H+-udbytning eller som diagnostikum samt lægemiddel med indhold deraf
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE19518796A1 (de) 1995-05-22 1996-11-28 Hoechst Ag Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19548812A1 (de) 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
DE19633966A1 (de) 1996-08-22 1998-02-26 Hoechst Ag Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JP4166433B2 (ja) * 1997-09-11 2008-10-15 第一製薬株式会社 ホルモン依存性疾患治療剤
DE19945302A1 (de) 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
DE10015248A1 (de) 2000-03-28 2001-10-04 Merck Patent Gmbh Bisamidino-Verbindungen als NHE-3 Inhibitoren
DE10019062A1 (de) 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
DE10043667A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline
DE10046993A1 (de) 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
DE10063294A1 (de) 2000-12-19 2002-07-04 Aventis Pharma Gmbh Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6736705B2 (en) 2001-04-27 2004-05-18 Hitachi Global Storage Technologies Polishing process for glass or ceramic disks used in disk drive data storage devices
US6911453B2 (en) 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
DE10161767A1 (de) 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163992A1 (de) 2001-12-24 2003-07-03 Merck Patent Gmbh 4-Aryl-chinazoline
GB0224830D0 (en) * 2002-10-24 2002-12-04 Sterix Ltd Compound
CN1254051C (zh) 2002-10-25 2006-04-26 华为技术有限公司 城域网传输设备中用户数据业务子速率传送方法
US6923466B2 (en) 2002-12-17 2005-08-02 James Tsai Collapsible handcart capable of extending the area of carrier by operating handle
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
WO2004113396A1 (ja) 2003-06-25 2004-12-29 Cmet Inc. 安定性の向上した活性エネルギー線硬化性の光学的立体造形用樹脂組成物
WO2005020612A1 (en) 2003-08-20 2005-03-03 Musky Communications (Proprietary) Limited Telephonic communication
SI1663185T1 (sl) * 2003-09-22 2009-04-30 Onepharm Res & Dev Gmbh Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
WO2005054705A2 (en) 2003-11-26 2005-06-16 Brian Judd Apparatus for dampening impact vibration in manual tools
US20050244367A1 (en) 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
KR20070038042A (ko) 2004-05-14 2007-04-09 파세코 코퍼레이션 컨테이너 핸들러들을 위한 상황 보고 디바이스들을 만드는장치 및 방법
DE102004046492A1 (de) 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102004054847A1 (de) 2004-11-13 2006-05-24 Sanofi-Aventis Deutschland Gmbh Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
MX2008005661A (es) 2005-11-03 2008-12-15 Ilypsa Inc Inhibidores de fosfolipasa, que incluyen inhibidores de fosfolipasa multivalente, y uso de los mismos, que incluyen como inhibidores de fosfolipasa localizadas en el lumen.
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
GB0604899D0 (en) 2006-03-10 2006-04-19 York Pharma Plc Derivatives of 18-glycyrrhetinic acid
GB0610009D0 (en) 2006-05-19 2006-06-28 Health Prot Agency Culture medium
GB2438389A (en) 2006-05-23 2007-11-28 Gkn Aerospace Transparency Sys Heating system for leading edge of aircraft
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
EP2228380A1 (en) 2009-03-13 2010-09-15 onepharm Research & Development GmbH Novel triterpene derivatives
KR101886467B1 (ko) 2011-01-31 2018-08-07 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드
US9120839B2 (en) 2012-08-14 2015-09-01 Nexoligo Co., Ltd. Ursolic acid derivative and method for preparing same
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
BR112015003516A2 (pt) 2012-08-21 2017-07-04 Ardelyx Inc compostos e métodos para inibição de antiporte mediado por nhe no tratamento de transtornos associados à retenção de fluido ou sobrecarga de sal e transtornos do trato gastrintestinal
TW201628631A (zh) 2014-12-23 2016-08-16 亞德利克斯公司 用於治療高血鉀症之組合物及方法

Similar Documents

Publication Publication Date Title
JP2020521740A5 (https=)
CA2672373A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2010509284A5 (https=)
JP2017528498A5 (https=)
JP2016504378A5 (https=)
JP2015500307A5 (https=)
KR102690885B1 (ko) 금속효소 억제제 화합물
JP2014513110A5 (https=)
JP2019521984A5 (https=)
JP2017519754A5 (https=)
JP2010520869A5 (https=)
JP2012528166A5 (https=)
AU2020207051B2 (en) Metalloenzyme inhibitor compounds
JP2010516635A5 (https=)
JP2010524898A5 (https=)
JP2012507525A5 (https=)
JP2015521156A5 (https=)
US12441718B2 (en) Selective angiotensin II compounds
JP2017515845A5 (https=)
JP2004525183A5 (https=)
JP2020529449A5 (https=)
JP2015524483A5 (https=)
IL300582A (en) New compounds for use in the treatment of angiotensin II-related diseases
JP2013525334A5 (https=)
JP2009501745A5 (https=)